Bridging from Warfarin to Enoxaparin in Patients with Factor V Leiden
Assessment of Thrombotic Risk
- Factor V Leiden mutation increases thrombotic risk but is considered a lower-risk thrombophilia compared to deficiencies of antithrombin, protein C, or protein S, and patients may require hematological consultation to determine their specific thrombotic risk profile 1
Bridging Protocol for Factor V Leiden Patients
Step 1: Discontinue Warfarin
- Stop warfarin 5 days before any planned procedure and check INR the day before to ensure it has decreased to ≤1.5, according to the American College of Chest Physicians 1, 2
Step 2: Initiate Enoxaparin
- For obese patients, consider using 0.8 mg/kg every 12 hours, as recommended by the Praxis Medical Insights 3
Step 3: Monitoring
- Anti-factor Xa monitoring is not routinely required for most patients on enoxaparin, but consider measuring anti-factor Xa levels in patients with severe renal impairment or extreme obesity, with a target anti-factor Xa level of 0.5-1.0 if monitoring is performed, as recommended by the American Heart Association 3, 4
Step 4: Dose Adjustments for Special Populations
- For patients with renal impairment, reduce dose to 1 mg/kg every 24 hours, as recommended by the Praxis Medical Insights 3
Duration of Bridging Therapy
- When resuming warfarin, overlap with enoxaparin until INR reaches therapeutic range, as recommended by the American Society of Hematology 5
Potential Complications and Management
- If bleeding occurs, consider protamine sulfate for partial neutralization of enoxaparin, and if thrombosis occurs despite prophylaxis, consider checking for additional thrombophilias, with patients occasionally requiring fresh-frozen plasma or antithrombin supplementation if they fail to achieve desired anti-Xa levels, as recommended by the American Heart Association 3, 4